Traws Pharma (FRA:0T2) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Days Payable?

Traws Pharma's average Accounts Payable for the three months ended in Dec. 2023 was €5.46 Mil. Traws Pharma's Cost of Goods Sold for the three months ended in Dec. 2023 was €0.00 Mil.

The historical rank and industry rank for Traws Pharma's Days Payable or its related term are showing as below:

FRA:0T2's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.29
* Ranked among companies with meaningful Days Payable only.

Traws Pharma's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Traws Pharma Days Payable Historical Data

The historical data trend for Traws Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Days Payable Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Traws Pharma's Days Payable

For the Biotechnology subindustry, Traws Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Days Payable falls into.

Traws Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Traws Pharma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (3.644	+	5.153)	/	2 )	/	0	*	365
=	4.3985					/	0	*	365
=	N/A

Traws Pharma's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (5.761	+	5.153)	/	2 )	/	0	*	365 / 4
=	5.457					/	0	*	365 / 4
=	N/A

Traws Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Traws Pharma (FRA:0T2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ONTX:USA

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines